FDA Approves Autoinjector for UCB’s Zilbrysq

Three years after its original approval, Zilbrysq (zilucoplan) is getting a second way to reach patients. On 16 October 2026, FDA approved a self-administered autoinjector presentation of UCB's once-daily complement C5 inhibitor for generalized myasthenia gravis — a device-only addition to an already-approved drug, built on bioequivalence and human-factors data rather than new efficacy trials.

A device supplement, read correctly

It is easy to mistake a new delivery device for a new drug approval, and the distinction matters for how a regulatory team should read this one. Zilucoplan itself, its approved indication, and its clinical efficacy claims are unchanged: this is FDA's approval of a second presentation — an autoinjector — for a macrocyclic peptide already on the market as a prefilled syringe since October 2023, when it was approved on the strength of the Phase 3 RAISE trial. The regulatory work behind a device-only supplement like this is narrower than a new efficacy program, but it is not trivial: a sponsor has to demonstrate the new device delivers the same drug exposure as the one already approved, and that patients and caregivers can use it correctly and safely without re-running the clinical trial that established the drug works.

Bioequivalence and human factors, not a new efficacy trial

UCB has said the autoinjector's approval rests on two kinds of data: bioequivalence studies bridging the autoinjector to the already-approved prefilled syringe, and human-factors and usability studies confirming correct self-administration. One trade report, citing UCB, puts a number on the usability work — 99.8% complete dose delivery across 449 administrations — but that figure traces to a single source in the reporting reviewed for this story, not to two independent outlets, so it is presented here as the company's own characterization rather than independently confirmed fact. For regulatory and quality teams managing their own prefilled-syringe-to-autoinjector transitions, particularly for biologics or peptides carrying a boxed warning, this is a current, concrete precedent for how FDA treats that device-change pathway: bridge the pharmacokinetics, prove the human factors, and the clinical indication itself does not need to be re-litigated.

What didn't change

Zilbrysq's boxed warning for serious meningococcal infections carries over to the autoinjector unchanged, along with FDA's recommendation that patients complete or update meningococcal vaccination at least two weeks before starting treatment, unless the risk of delaying treatment outweighs the infection risk. The most common adverse reactions reported in 10% or more of patients in the original approval — injection site reactions, upper respiratory tract infection, and diarrhea — also remain the reference safety profile; this device supplement did not generate a new efficacy or long-term safety dataset of its own. UCB has said it expects the autoinjector to reach the market commercially in the first quarter of 2027.

What this outlet could not independently confirm

The specific supplemental application number and type for this device addition were not identified in the trade coverage reviewed for this story, nor was it possible to confirm whether FDA required any update to Zilbrysq's REMS program alongside the device change. FDA's own approval letter and UCB's full press release were not directly accessible from this reporting environment; readers relying on the application number, REMS status, or the 99.8%/449-administration usability figure for submission planning should confirm them against FDA's approval letter or UCB's primary materials once available.

Frequently asked questions

What did FDA approve on 16 October 2026?

A self-administered autoinjector presentation of Zilbrysq (zilucoplan) for adults with anti-AChR antibody-positive generalized myasthenia gravis — a new delivery device for an already-approved drug, not a new indication. Zilbrysq was first approved in October 2023 as a prefilled syringe, based on the Phase 3 RAISE trial.

What evidence supported the new device?

Bioequivalence data bridging the autoinjector to the existing prefilled syringe, plus human-factors and usability studies. UCB has cited 99.8% complete dose delivery across 449 administrations in a usability study — a figure this outlet could not independently corroborate beyond the single source reporting it.

Does the safety profile change?

No. The existing boxed warning for serious meningococcal infections and the pre-treatment vaccination recommendation carry over unchanged, as do the most common adverse reactions from the original approval: injection site reactions, upper respiratory tract infection, and diarrhea.

When will the autoinjector be available?

UCB has said it expects commercial availability in the first quarter of 2027.